Read Part 1

Detection and diagnosis
Treatment initiation
Untreated patients

Most Canadian patients with multiple sclerosis learn they may have MS from their family doctor or other healthcare professional rather than a neurologist, according to the results of a recent survey. From February to May 2025, Lind Publishing conducted twin surveys of MS healthcare professionals on NeuroSens and of MS patients on its sister website MSology (www.msology.com). There were 64 responses to the HCP survey and 66 responses to the patient survey. Read More

Read Part 2

Part 1

A majority of patients with multiple sclerosis in Canada are advised to start treatment with a disease-modifying therapy, most commonly with an anti-CD20 treatment, according to the results of a recent survey on NeuroSens. The survey was conducted from 27 February-31 March 2025 and received 64 responses from MS neurologists and nurses. Read More

The newly-published Discontinuing Disease-modifying Therapies in Stable Relapsing-onset Multiple Sclerosis (DOT-MS) is the second important trial to examine the feasibility of discontinuing disease-modifying therapy (DMT) in patients with multiple sclerosis (Coerver et al. JAMA Neurol 2025;82:123-131). Read More